Advertisement
New findings have important implications for clinical trial design
New research explores the role of immune cell and blood-brain barrier changes
Open-source artificial intelligence technology uses human genetic data to find candidate drugs
Experts weigh in on the amyloid hypothesis and how to use lecanemab if approved
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Findings underscore need for racial diversity in ongoing and future trials
Investigative highlights include hormone therapies, biomarkers and early lifestyle interventions
Will enable sharper focus on new diagnostic tools for elusive neurodegenerative disease
Neuropsychological, serum and MRI measures improve over time relative to active fighters
Risk of agitation, delusions, personality change and more is shaped by early presentation
69% relative risk reduction in large database analysis prompts plans for mechanistic and phase 2 studies
Advertisement
Advertisement